Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Similar articles for PubMed (Select 23701295)

1.

Icosapent ethyl for the treatment of hypertriglyceridemia.

Ballantyne CM, Braeckman RA, Soni PN.

Expert Opin Pharmacother. 2013 Jul;14(10):1409-16. doi: 10.1517/14656566.2013.798645. Epub 2013 May 24.

PMID:
23701295
2.

Icosapent ethyl for treatment of elevated triglyceride levels.

Nelson SD, Munger MA.

Ann Pharmacother. 2013 Nov;47(11):1517-23. doi: 10.1177/1060028013504079. Epub 2013 Nov 5. Review.

PMID:
24259598
3.

Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.

Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN.

Am J Cardiovasc Drugs. 2013 Feb;13(1):37-46. doi: 10.1007/s40256-012-0002-3.

4.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).

Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN.

J Clin Lipidol. 2012 Nov-Dec;6(6):565-72. doi: 10.1016/j.jacl.2012.07.001. Epub 2012 Jul 24.

PMID:
23312052
5.

Icosapent ethyl: a review of its use in severe hypertriglyceridemia.

Kim ES, McCormack PL.

Am J Cardiovasc Drugs. 2014 Dec;14(6):471-8. doi: 10.1007/s40256-014-0099-7. Review.

PMID:
25428605
6.

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.

Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN.

Cardiovasc Diabetol. 2013 Jul 9;12:100. doi: 10.1186/1475-2840-12-100.

7.

Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.

Weintraub HS.

Postgrad Med. 2014 Nov;126(7):7-18. doi: 10.3810/pgm.2014.11.2828. Review.

PMID:
25387209
8.

Overview of omega-3 Fatty Acid therapies.

Bradberry JC, Hilleman DE.

P T. 2013 Nov;38(11):681-91.

9.

Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.

Weintraub H.

Atherosclerosis. 2013 Oct;230(2):381-9. doi: 10.1016/j.atherosclerosis.2013.07.041. Epub 2013 Jul 31. Review.

10.

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol. 2012 Oct 1;110(7):984-92. doi: 10.1016/j.amjcard.2012.05.031. Epub 2012 Jul 20.

PMID:
22819432
11.
12.

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol. 2011 Sep 1;108(5):682-90. doi: 10.1016/j.amjcard.2011.04.015. Epub 2011 Jun 16.

PMID:
21683321
13.

A new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial.

Jacobson TA.

Expert Rev Cardiovasc Ther. 2012 Jun;10(6):687-95. doi: 10.1586/erc.12.56.

PMID:
22894624
14.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).

Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN.

Prostaglandins Leukot Essent Fatty Acids. 2013 Sep;89(4):195-201. doi: 10.1016/j.plefa.2013.07.005. Epub 2013 Aug 1.

PMID:
23992935
15.

Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review.

Jacobson TA, Glickstein SB, Rowe JD, Soni PN.

J Clin Lipidol. 2012 Jan-Feb;6(1):5-18. doi: 10.1016/j.jacl.2011.10.018. Epub 2011 Nov 3. Review.

PMID:
22264569
16.

Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.

McKenney JM, Sica D.

Pharmacotherapy. 2007 May;27(5):715-28. Review.

PMID:
17461707
17.

Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.

Bays HE, Tighe AP, Sadovsky R, Davidson MH.

Expert Rev Cardiovasc Ther. 2008 Mar;6(3):391-409. doi: 10.1586/14779072.6.3.391. Review.

PMID:
18327998
18.

Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl.

Hassan A, Tajuddin N, Shaikh A.

Cardiol Ther. 2015 Jun;4(1):83-93. doi: 10.1007/s40119-014-0032-9. Epub 2014 Dec 17.

19.

Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians.

Bays H.

Drugs Today (Barc). 2008 Mar;44(3):205-46. doi: 10.1358/dot.2008.44.3.1166387.

PMID:
18536782
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk